ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Plozasiran Update On January 17, 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that the U.S. Food and Drug Administration (FDA) ...

The company projects plozasiran to generate $2 billion to $3 billion annually in the SHTG market alone, with Phase III studies (SHASTA-3, SHASTA-4, and MUIR 3) expected to complete enrollment this ...

During the recent period, Arrowhead (ARWR) signed and closed a potentially transformational licensing and collaboration agreement with Sarepta ...

Certain foods have generated devoted followings among people from all walks of life. While flavorful foods can be hard to resist, some wildly popular items found in refrigerators and pantries ...

Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...

Shares of 89bio (NASDAQ:ETNB) were up 40% Monday afternoon, stoked by positive data for Akero Therapeutics' (NASDAQ:AKRO) drug efruxifermin in the treatment of compensated liver cirrhosis due to MASH.

Plozasiran sodium (AROAPOC-3) is under development for the treatment of severe hypertriglyceridemia, mixed dyslipidemia and familial Chylomicronemia. It is administered through the subcutaneous route.

This is not one but a group of risk factors for heart disease, stroke, and diabetes. Many ways that hypertriglyceridemia is treated are also the same measures used to prevent it. High triglyceride ...

SAN FRANCISCO--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation ...

Nearly one-half of US counties have no practicing cardiologists. These counties with limited access to cardiovascular care tend to be more rural and socioeconomically disadvantaged, with a greater ...

The U.S. Food and Drug Administration (FDA) announced on April 15 that Abbott/Thoratec Corp. is recalling the Heartmate II and Heartmate 3 Left Ventricular Assist System (LVAS) due to long-term ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...